التفاصيل البيبلوغرافية
| العنوان: |
Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. |
| المؤلفون: |
Rocco, Alba, Compare, Debora, Coccoli, Pietro, Esposito, Ciro, Spirito, Antimo Di, Barbato, Antonio, Strazzullo, Pasquale, Nardone, Gerardo |
| المصدر: |
Gut; May2013, Vol. 62 Issue 5, p766-773, 8p, 1 Diagram, 6 Charts, 2 Graphs |
| مصطلحات موضوعية: |
VITAMIN B12 metabolism, HEPATITIS C virus, HEALTH risk assessment, ANTIVIRAL agents, GENETIC polymorphisms, INTERLEUKINS, PATIENTS |
| مستخلص: |
Background In vitro, vitamin B12 acts as a natural inhibitor of hepatitis C virus (HCV) replication. Objective To assess the effect of vitamin B12 on virological response in patients with chronic HCV hepatitis naïve to antiviral therapy. Methods Ninety-four patients with chronic HCV hepatitis were randomly assigned to receive pegylated interferon a plus ribavirin (standard-of-care; SOC) or SOC plus vitamin B12 (SOC+B12). Viral responsednamely, undetectable serum HCV-RNA, was evaluated 4 weeks after starting treatment (rapid viral response), 12 weeks after starting treatment (complete early viral response) and 24 or 48 weeks after starting treatment (end-oftreatment viral response) and 24 weeks after completing treatment (sustained viral response (SVR)). Genotyping for the interleukin (IL)-28B polymorphism was performed a posteriori in a subset (42/64) of HCV genotype 1 carriers. Results Overall, rapid viral response did not differ between the two groups, whereas the rates of complete early viral response (p=0.03), end-of-treatment viral response (p=0.03) and SVR (p=0.001) were significantly higher in SOC+B12 patients than in SOC patients. In SOC+B12 patients, the SVR rate was also significantly higher in carriers of a difficult-to-treat genotype (p=0.002) and in patients with a high baseline viral load (p=0.002). Distribution of genotype IL-28B did not differ between the two groups. At multivariate analysis, only easy-to-treat HCV genotypes (OR=9.00; 95% CI 2.5 to 37.5; p=0.001) and vitamin B12 supplementation (OR=6.9; 95% CI 2.0 to 23.6; p=0.002) were independently associated with SVR. Conclusion Vitamin B12 supplementation significantly improves SVR rates in HCV-infected patients naïve to antiviral therapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Gut is the property of BMJ Publishing Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
